Nuevolution provides update on the positive progress in partnerships & pipeline and consolidation of its business & patent strategy

Stockholm, 14 December 2018. Yesterday, Nuevolution’s Board of Directors and Management performed its half-year review of the company’s portfolio of development programs and associated business and patent strategy.

Summary

  • Positive progress observed in all existing partnerships and across own programs
  • Strong commitment to continue investments in realizing success from existing partnerships
  • New business opportunities to remain focused on partnerships with true long-term value
  • Increased monitoring and potential legal enforcement actions to be taken of potential infringement of the company’s 274 granted technology platform patents

Partnered and own projects

The Board concluded that Nuevolution’s partnered projects with Almirall, Amgen and Janssen all continue to progress positively and as planned.

The company’s broad portfolio of own programs has matured very well during the last six months, with two new attractive programs (RIPK1 and TYK2) being rapidly progressed. The IL-17A program recently presented positive effect in an important animal model for psoriasis, and the company’s BET BD1 program is on-track towards program candidate nomination shortly.

Business strategy

The Board reiterated the company’s commitment and its business focus on realizing success from its existing partnerships, and to diligently pursue new partnerships, but maintain focus on partnerships that offer true long-term value to the company and its shareholders.

Nuevolution operates the world’s largest and most drug-like research platform (Chemetics®) for discovery of tablet-based (small molecules) medicines. The platform also includes a completely revised process for optimization of screening hit molecules to development program candidates compared to the industry conventional approach. Nuevolution’s powerful approach provide significantly faster access to a considerable higher number of advanced molecules of higher quality throughout the research phase.

Nuevolution’s drug discovery approach accelerates projects from idea to highly valuable candidate assets as demonstrated by the broad portfolio of high-quality programs (partnered and own) that has been established and further progressed.

In pursuit of partnerships, Nuevolution will therefore continue to have its focus on collaborations that allows Nuevolution to deploy its complete platform and skills beyond simple screening activities to maximize value generated for partners and Nuevolution.

Business activities

Partnership discussions has progressed positively and have been focused around:

  • Research & Development collaborations
  • Platform-based collaborations
  • Out-licensing of Nuevolution’s programs

Strong patent position

To protect the application of its proprietary drug discovery platform, Nuevolution maintains its investments to keep and expand its strong and broad patent position with 274 granted patents representing thousands of patent claims protecting all operational and product aspects.

Nuevolution’s board and management has decided to increase the monitoring of the technology platform field for potential infringement of its patent estate and may take legal actions to enforce patent rights as appropriate, and as optimal for the company’s business strategy.

The board concluded in summary that positive progress has been realized across a broad front of activities.

For more information, please contact:

Stig Løkke Pedersen
Chairman of the Board of Directors
Phone: +45 4086 4151

Alex Haahr Gouliaev
Chief Executive Officer
Phone: +45 7020 0987

 

Information about Nuevolution AB (publ)

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and develops its programs alone and in collaboration with pharmaceutical and biotechnology companies to seek future benefit for patients in need of novel medical treatment options. Nuevolution’s internal programs are focused on therapeutically important diseases targets within severe inflammatory diseases and cancer.

This information is information that Nuevolution AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact persons set out above, on Friday 14 December 2018 at 15:00 CET.

Nuevolution AB (publ) is listed at Nasdaq in Stockholm, Sweden (ticker: NUE). More information about Nuevolution can be found on: www.nuevolution.com